Biontech and ryvu therapeutics enter into global collaboration to develop and commercialize immuno-modulatory small molecule candidates

Mainz, germany and krakow, poland – november 30, 2022 – biontech se (nasdaq: bntx, “biontech”) and ryvu therapeutics s.a. (warsaw stock exchange: rvu, “ryvu”), a clinical-stage company developing oncology therapeutics today announced that the companies have entered into a multi-target research collaboration for several small molecule immunotherapy programs as well as an exclusive license agreement for ryvu's sting agonist portfolio as standalone small molecules.
BNTX Ratings Summary
BNTX Quant Ranking